Beranda › Kanker Ginjal (Karsinoma Sel Renal) › Texas › Houston
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di Houston, TX
35 studi untuk Kanker Ginjal (Karsinoma Sel Renal) mencari peserta di lokasi sekitar Houston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- NEO-811 Houston Site, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- UT MD Anderson Cancer Center, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Menerima pesertaFase 1/2
- University of Texas - MD Anderson Cancer Center, Houston
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Menerima pesertaFase 2
- UT MD Anderson Cancer Center, Houston
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Menerima pesertaFase 1/2
- MD Anderson Cancer Center, Houston
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Menerima pesertaFase 2
- M D Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Menerima pesertaFase 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- dan 1 lainnya
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Menerima pesertaFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Menerima pesertaFase 1
- Md Anderson Cancer Center, Houston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Menerima pesertaFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Methodist Willowbrook Hospital, Houston
- dan 1 lainnya
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 2
- MD Anderson Cancer Center, Houston
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Menerima pesertaFase 2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Houston Methodist Hospital, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Menerima pesertaFase 1
- The University of Texas M. D. Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Menerima pesertaFase 1
- MD Anderson Cancer Center, Houston
PET/MR for Characterization of Renal Masses (RMs)
Menerima pesertaStudi observasional
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Menerima pesertaFase 1/2
- MD Anderson Cancer Center, Houston
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- UT MD Anderson, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Menerima pesertaFase 1
- M D Anderson Cancer Center, Houston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Menerima pesertaFase 1/2
- MD Anderson Cancer Center, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Menerima pesertaFase 1
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Menerima pesertaFase 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Menerima pesertaFase 2
- MD Anderson Cancer Center, Houston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 2
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Menerima pesertaFase 1/2
- MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Menerima peserta
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Menerima pesertaFase 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
Menerima pesertaFase 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Menerima pesertaFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Menerima pesertaFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Menerima pesertaFase 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di kota lain
- New York City, NY27 studi
- Dallas, TX23 studi
- Nashville, TN23 studi
- St. Louis, MO23 studi
- Los Angeles, CA20 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Jacksonville, FL14 studi
- Cleveland, OH14 studi
Studi lain di Houston
- Kanker Paru Non-Sel Kecil145 studi
- Kanker Payudara126 studi
- Kanker (semua jenis)121 studi
- Kanker Metastatik104 studi
- Kanker Kolorektal102 studi
- Kanker Ovarium89 studi
- Leukemia Mieloid Akut85 studi
- Kanker Paru78 studi
- Kanker Prostat76 studi
- Kanker Endometrium68 studi
- Kanker Pankreas61 studi
- Melanoma59 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.